ORELVO Trademark

Trademark Overview

On Tuesday, September 12, 2017, a trademark application was filed for ORELVO with the United States Patent and Trademark Office. The USPTO has given the ORELVO trademark a serial number of 87604397. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, April 19, 2021. This trademark is owned by Aurinia Pharmaceuticals Inc.. The ORELVO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune disorders, kidney disorders, opthamalogical disorders and lupus nephritis
orelvo

General Information

Serial Number87604397
Word MarkORELVO
Filing DateTuesday, September 12, 2017
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, April 19, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune disorders, kidney disorders, opthamalogical disorders and lupus nephritis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 15, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAurinia Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressV8Z 7X8
CA

Trademark Events

Event DateEvent Description
Tuesday, April 20, 2021ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, April 19, 2021ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, April 19, 2021ASSIGNED TO EXAMINER
Thursday, October 1, 2020NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, October 1, 2020INQUIRY TO SUSPENSION E-MAILED
Thursday, October 1, 2020SUSPENSION INQUIRY WRITTEN
Wednesday, September 9, 2020LIE CHECKED SUSP - TO ATTY FOR ACTION
Wednesday, March 4, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, March 4, 2020LETTER OF SUSPENSION E-MAILED
Wednesday, March 4, 2020SUSPENSION LETTER WRITTEN
Monday, February 10, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 10, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 5, 2020TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, September 9, 2019NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, September 9, 2019INQUIRY TO SUSPENSION E-MAILED
Monday, September 9, 2019SUSPENSION INQUIRY WRITTEN
Thursday, August 22, 2019LIE CHECKED SUSP - TO ATTY FOR ACTION
Thursday, February 21, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, February 21, 2019LETTER OF SUSPENSION E-MAILED
Thursday, February 21, 2019SUSPENSION LETTER WRITTEN
Thursday, January 31, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 31, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 30, 2019TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Saturday, August 4, 2018NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Saturday, August 4, 2018INQUIRY TO SUSPENSION E-MAILED
Saturday, August 4, 2018SUSPENSION INQUIRY WRITTEN
Friday, July 13, 2018LIE CHECKED SUSP - TO ATTY FOR ACTION
Wednesday, July 11, 2018ASSIGNED TO LIE
Friday, December 15, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, December 15, 2017LETTER OF SUSPENSION E-MAILED
Friday, December 15, 2017SUSPENSION LETTER WRITTEN
Friday, December 15, 2017ASSIGNED TO EXAMINER
Friday, September 15, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, September 15, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

orelvo disorders opthamalogical lupus nephritis kidney pharmaceutical treatment autoimmune preparations